Clinical Trials Information
For questions about clinical trial information, please email email@example.com
Nektar Therapeutics is focused on the clinical development of our investigational medicines to evaluate them for both safety and efficacy, especially for medical conditions where there are no effective approved medicines.
Before a new therapy can be made available to the general public, rigorous tests involving multiple studies on human volunteers are required. These studies, referred to as clinical trials, are carefully conducted and are regulated by the Food and Drug Administration (FDA) in the United States and by similar regulatory agencies worldwide. Participation in clinical trials allows patients to potentially gain access to the latest investigational treatments at little to no cost, while also playing a vital role in advancing medicine.
Nektar Therapeutics is recruiting patients in the U.S. and other countries for the following active clinical trials. Please follow the links below for more information on the enrollment criteria for each study and site location:
A phase 1/2, dose-escalation and dose-expansion study of NKTR-255 in combination with cetuximab in patients with refractory 2nd and 3rd line metastatic colorectal cancer or metastatic head and neck cancer
A phase 1, open-label, multi-center, dose escalation and dose expansion study of NKTR-255 as a single agent in relapsed or refractory Hematological Malignancies and in combination with daratumumab as a salvage regimen for multiple Myeloma
Further information and background on clinical trials may be found on www.clinicaltrials.gov, a service of the U.S. National Institutes of Health (NIH).